These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 38967722)
1. Ultrasensitive detection of uveal melanoma using [ Wang L; Zhu X; Xue Y; Huang Z; Zou W; Zhang Z; Yu M; Pan D; Wang K EJNMMI Res; 2024 Jul; 14(1):62. PubMed ID: 38967722 [TBL] [Abstract][Full Text] [Related]
2. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Gao H; Lang L; Guo N; Cao F; Quan Q; Hu S; Kiesewetter DO; Niu G; Chen X Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):683-92. PubMed ID: 22274731 [TBL] [Abstract][Full Text] [Related]
3. Comparison of 18 F-AlF-NOTA-PRGD2 and 18 F-FDG PET/CT Imaging in a Case of Primary Uveal Melanoma. Zhu X; Pan D; Zhang Z; Wang K; Zou W Clin Nucl Med; 2024 May; 49(5):489-490. PubMed ID: 38465994 [TBL] [Abstract][Full Text] [Related]
4. [Tumor targeting efficacy of a novel PET radiotracer (1)8F-AlF-NOTA-PRGD2 in mice]. Wu H; Wang Q; Han Y; Zhou W; Li H; Tian Y; Wang Q Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jan; 34(1):51-5. PubMed ID: 24463116 [TBL] [Abstract][Full Text] [Related]
5. The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG. Cui Y; Liu H; Liang S; Zhang C; Cheng W; Hai W; Yin B; Wang D Oncotarget; 2016 May; 7(19):27243-54. PubMed ID: 27029065 [TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model. Guo N; Lang L; Li W; Kiesewetter DO; Gao H; Niu G; Xie Q; Chen X PLoS One; 2012; 7(5):e37506. PubMed ID: 22624041 [TBL] [Abstract][Full Text] [Related]
7. Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer. Chen L; Fu H; He H; Lou K; Li Q; Ye J; Feng G; Yu C Mol Pharm; 2023 Aug; 20(8):4277-4284. PubMed ID: 37463487 [TBL] [Abstract][Full Text] [Related]
8. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model. Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694 [TBL] [Abstract][Full Text] [Related]
9. [ Wang Y; Zhang Y; Chen Y; Wang S; Liu W; Liu Z; Hu M Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3161-3175. PubMed ID: 38713298 [TBL] [Abstract][Full Text] [Related]
10. PET imaging of CXCR4 expression using [ Cheng K; Wang S; Liu T; Pei J; Wang S; Liu J; Zhao K; Luo Y; Xu S; Yu J; Liu J Theranostics; 2024; 14(16):6337-6349. PubMed ID: 39431004 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and Evaluation of [ Huang J; Bai L; Shi D; Jiang W; Chen P; Dong Y; Zhang X; Peng J; Hou J; Lu Y; Huang X; Tang G; Huang S Mol Pharm; 2024 May; 21(5):2425-2434. PubMed ID: 38554143 [TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation and pilot clinical study of [ Ge L; Fu Z; Wei Y; Shi D; Geng Y; Fan H; Zhang R; Zhang Y; Li S; Wang S; Shi H; Song G; Pan J; Cheng K; Wang L Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4025-4036. PubMed ID: 35715613 [TBL] [Abstract][Full Text] [Related]
13. [ Wei Y; Zheng J; Ma L; Liu X; Xu S; Wang S; Pei J; Cheng K; Yuan S; Yu J Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2761-2773. PubMed ID: 35262766 [TBL] [Abstract][Full Text] [Related]
14. Comparison of 18F-AIF-NOTA-PRGD2 and 18F-FDG uptake in lymph node metastasis of differentiated thyroid cancer. Cheng W; Wu Z; Liang S; Fu H; Wu S; Tang Y; Ye Z; Wang H PLoS One; 2014; 9(6):e100521. PubMed ID: 24956393 [TBL] [Abstract][Full Text] [Related]
15. Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT Can Discriminate Uncommon Meningioma Mimicking High-Grade Glioma. Li D; Zhang J; Ji N; Zhao X; Zheng K; Qiao Z; Li F; Lang L; Iagaru A; Niu G; Zhu Z; Chen X Clin Nucl Med; 2018 Sep; 43(9):648-654. PubMed ID: 30052597 [TBL] [Abstract][Full Text] [Related]
16. [ Liu Z; Wen G; Huang Y; Dong Y; Wang Z; Alhaskawi A; Zhang S; Wang G; Ye Q; Zhou H; Lu H; Dong M Front Oncol; 2023; 13():1126721. PubMed ID: 37284201 [TBL] [Abstract][Full Text] [Related]
17. 68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer. Zheng K; Liang N; Zhang J; Lang L; Zhang W; Li S; Zhao J; Niu G; Li F; Zhu Z; Chen X J Nucl Med; 2015 Dec; 56(12):1823-7. PubMed ID: 26429958 [TBL] [Abstract][Full Text] [Related]
18. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Lang L; Li W; Guo N; Ma Y; Zhu L; Kiesewetter DO; Shen B; Niu G; Chen X Bioconjug Chem; 2011 Dec; 22(12):2415-22. PubMed ID: 22026940 [TBL] [Abstract][Full Text] [Related]
19. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy. Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029 [TBL] [Abstract][Full Text] [Related]
20. [ Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]